Response to Comments
Midwest CEPAC

PDF cover

Ovarian Cancer: ICER’s Response to Public Comments

ICER’s response to public comments received on a Draft Evidence Report for PARP inhibitors for ovarian cancer.

View

View All Materials on this Topic or Go Back to View More Materials